Cat. No. | Product Name | Field of Application | Chemical Structure |
---|---|---|---|
DC22564 | NVP-MELK8a hydrochloride Featured |
NVP-MELK8a hydrochloride (MELK8a hydrochloride) is a novel potent, and selective MELK inhibitor with IC50 of 2 nM.
More description
|
![]() |
DC33535 | NMS-E973 Featured |
NMS-E973 is a novel, selective and potent inhibitor of heat shock protein 90 (Hsp90). NMS-E973 displays significant efficacy in a human ovarian A2780 xenograft tumor model, with a mechanism of action confirmed in vivo by typical modulation of known Hsp90 client proteins, and with a favorable pharmacokinetic and safety profile. The efficacy profile of NMS-E973 suggests a potential for development in different clinical settings, including tumors that have become resistant to molecular targeted agents, particularly in cases of tumors which reside beyond the blood-brain barrier (BBB).
More description
|
![]() |
DC26131 | Timapiprant sodium Featured |
Timapiprant sodium (OC000459 sodium) is a potent, selective, and orally active D prostanoid receptor 2 (DP2, also known as CRTH2) antagonist.
More description
|
![]() |
DC11046 | SR2211 Featured |
SR2211 (SR-2211) is a potent, selective RORγ inverse agonist (Ki=105 nM, IC50=320 nM) that potently inhibits production of IL-17 in cells.
More description
|
![]() |
DC29051 | Perospirone Featured |
Perospirone (SM-9018 free base) is an orally active antagonist of 5-HT2A receptor (Ki=0.6 nM) and dopamine D2 receptor (Ki=1.4 nM), and also a partial agonist of 5-HT1A receptor (Ki=2.9 nM). Perospirone is an atypical antipsychotic drug and has the potential for schizophrenic disease treatment.
More description
|
![]() |
DCC5082 | Teijin Compound 1 Hydrochloride Featured |
CCR2 antagonist 4 hydrochloride (Teijin compound 1 hydrochloride) is a potent and specific CCR2 antagonist, with IC50s of 180 nM for CCR2b. CCR2 antagonist 4 hydrochloride potently inhibits MCP-1-induced chemotaxis with an IC50 of 24 nM.
More description
|
![]() |
DC28447 | Lofepramine Featured |
Lofepramine (Lopramine) is a potent tricyclic antidepressant and is extensively metabolised to Desipramine. The antidepressant activity of Lofepramine stems from the facilitation of noradrenergic neurotransmission by uptake inhibition. Lofepramine may also potentiate serotoninergic neurotransmission by inhibition of the neuronal uptake of serotonin and the enzyme tryptophan pyrrolase. Lofepramine has significant anxiolytic efficacy in addition to its antidepressant properties.
More description
|
![]() |
DC9583 | Oglemilast Featured |
Oglemilast(GRC3886) is a potent PDE4 inhibitor, under clinical studies in the treatment of allergen-induced asthma.
More description
|
![]() |
DC45911 | JC124 Featured |
JC124 is a specific NLRP3 inflammasome inhibitor. JC124 has anti-inflammatory and neuroprotective effects.
More description
|
![]() |
DCAPI1119 | Cathepsin Inhibitor 1 Featured |
Cathepsin Inhibitor 1 is an inhibitor of Cathepsin (L, L2, S, K, B) with pIC50 of 7.9, 6.7, 6.0, 5.5 and 5.2, respectively.
More description
|
![]() |
DC34568 | LP935509 Featured |
LP-935509 is a potent inhibitor of the Adapter protein-2 Associated Kinase 1 (AAK1).
More description
|
![]() |
DC8211 | SR10067 Featured |
For the detailed information of SR10067, the solubility of SR10067 in water, the solubility of SR10067 in DMSO, the solubility of SR10067 in PBS buffer, the animal experiment (test) of SR10067, the cell expriment (test) of SR10067, the in vivo, in vitro and clinical trial test of SR10067, the EC50, IC50,and affinity,of SR10067, For the detailed information of SR10067, the solubility of SR10067 in water, the solubility of SR10067 in DMSO, the solubility of SR10067 in PBS buffer, the animal experiment (test) of SR10067, the cell expriment (test) of SR10067, the in vivo, in vitro and clinical trial test of SR10067, the EC50, IC50,and affinity,of SR10067, Please contact DC Chemicals..
More description
|
![]() |
DC8743 | NVP-BVU972 Featured |
NVP-BVU972 is a selective and potent Met inhibitor (IC50 = 14 nM). Antitumor agents.
More description
|
![]() |
DC33304 | LSN2463359 Featured |
LSN2463359 is a novel positive allosteric modulators of the mGlu? receptor.
More description
|
![]() |
DC46527 | σ1 Receptor antagonist-1 Featured |
σ1 Receptor antagonist-1 is a highly potent and selective sigma 1 receptor antagonist (pKi=10.28). σ1 Receptor antagonist-1 inhibits cell growth, arrests cell cycle at G0/G1 phase and induces apoptosis of MCF-7/ADR cells.
More description
|
![]() |
DC10167 | ZINC00881524 Featured |
ZINC00881524 is a ROCK inhibitor.
More description
|
![]() |
DC23074 | Sivelestat Featured |
A potent, specific and competitive inhibitor of human neutrophil elastase with IC50 of 44 nM.
More description
|
![]() |
DC73763 | CC-11050 Featured |
Dovramilast (CC-11050) is a potent and orally active phosphodiesterase 4 (PDE4) inhibitor, CC-11050 is a promising candidate for host directed therapy of patients with pulmonary TB.
More description
|
![]() |
DC31417 | BVD-523 hydrochloride Featured |
Ulixertinib, also known as BVD-523 and VRT752271, is an inhibitors of ERK protein kinase. Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Upon oral administration, BVD-523 inhibits both ERK 1 and 2, thereby preventing the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.
More description
|
![]() |
DC32815 | DY-268 Featured |
DY-268 is a trisubstituted-pyrazol carboamide based compound that acts as a potent FXR antagonist (IC50 = 7.5 nM). It does not display any FXR agonistic activity and cytotoxicity.
More description
|
![]() |
DC47053 | Tigulixostat Featured |
Tigulixostat is a novel (indolyl)heteroarylcarboxylate derivatives effective as non-purine selective xanthine oxidase inhibitor, which lowers the production of uric acid.
More description
|
![]() |
DC48418 | SR15006 Featured |
SR15006 is a inhibitor of Krüppel-like factor 5 (KLF5) with an IC50 of 41.6 nM in DLD-1/pGL4.18hKLF5p cells).
More description
|
![]() |
DC49872 | GSK854 Featured |
GSK854 is a potent Inhibitor of Troponin I-Interacting Kinase (TNNI3K). GSK854 is a suitable lead for identifying new cardiac medicines and have been employed as in vivo tools in investigational studies aimed at defining the role of TNNI3K within heart failure.
More description
|
![]() |
DC11905 | Opiranserin Featured |
Opiranserin (VVZ-149, VVZ-000149) is a potent, selective, mixed glycine GlyT2 transporter blocker (IC50= 0.86 uM), purine P2X3 receptor antagonist (IC50=0.87 uM) and serotonin 5-HT2A receptor antagonist (IC50=1.3 uM).
More description
|
![]() |
DC24030 | LY451395 Featured |
A potent, selective, and centrally active positive allosteric modulator of AMPAR-mediated neurotransmission, which increase ion channel flux in the presence of agonist by suppressing desensitization and/or deactivation of the receptors..
More description
|
![]() |
DC45705 | Thalidomide-NH-PEG1-NH2 hydrochloride Featured |
Thalidomide-NH-PEG1-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
More description
|
![]() |
DC22745 | SLx-4090 Featured |
A novel potent, selective and orally active enterocytic microsomal triglyceride transfer protein (MTP) inhibitor that inhibits only MTP localized to enterocytes with IC50 of 6 nM.
More description
|
![]() |
DC7245 | SB 222200 Featured |
SB 222200 is a selective, reversible and competitive antagonist of human NK-3 receptor(Ki=4.4 nM) that effectively crosses the blood-brain barrier.
More description
|
![]() |
DC7554 | SGC-CBP30 Featured |
SGC-CBP30 is a potent CREBBP/EP300 inhibitor with IC50 of 21 nM and 38 nM, respectively.
More description
|
![]() |
DC49965 | CHD1Li 6.11 Featured |
CHD1Li 6.11 is a potent oncogenic CHD1L inhibitor (IC50=3.3 µM for cat-CHD1L recombinant protein). CHD1Li 6.11 is an orally bioavailable antitumor agent, significantly reducing the tumor volume of CRC xenografts generated from isolated quasi mesenchymal cells (M-phenotype), which possess enhanced tumorigenic properties.
More description
|
![]() |